International Parkinson and Movement Disorders Society Congress (MDS)

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.

The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.

The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.

Acorda Therapeutics’ Inbrija, an inhalation powder formulation of levodopa, was associated with no significant increases in troublesome dyskinesia for patients being treated with carbidopa/levodopa.

Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.

Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study.

Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.

When considering treatment strategies for dementia, clinicians often focus on Alzheimer disease. However, Lewy body dementia also leads to a decline in cognition, movement, and mood and behavior.

Both low fat and ketogenic diets appear to be safe and may be even salutary in patients with Parkinson disease, according to new research.

The latest research includes the development of novel device therapies, MRI-guided focused ultrasound, and DBS surgery.

Cutting-edge insights on the value of deep brain stimulation of the subthalamic nucleus in Parkinson disease.

Early diagnosis of PD and the initiation of neuroprotective treatment may alter the disease course, improving the quality of life for patients.

Findings indicate that some CAM therapies may have a promising future in the management of Parkinson disease.

Experts present the latest on the mechanisms and management of psychotic features in PD and Lewy body dementia.

Stem cell transplantation for treatment of Parkinson disease is complex and requires both surgery and acquisition of stem cells. What does the future hold?

In addition to the most up-to-date management approaches to tremors and other issues related to Parkinson disease, the conference will cover a vast array of other offerings. Neurology Times will provide daily updates for those attending in person or remotely. Get your quick intro here.

You’ll want to get to bed early on Thursday, because you’ll have a very full week ahead. And even if you can't make #MDSCongress, October 5-9, 2018, get your highlights and Editor's Picks here.